New data uncovers Invokana's 'protective effect'

The Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has presented important results on Invokana (canagliflozin) at the American Diabetes Association (ADA) meeting.

A new subgroup analysis from the landmark Phase III CREDENCE study shows that Invokana significantly reduced the risk of major cardiovascular (CV) events and kidney failure in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

"Invokana is now poised to become the first therapy in nearly two decades for treating CKD in people with T2D"These positive results were observed in those with CV risk factors but no history of CV disease and patients with a history of CV disease, defined as having experienced coronary, cerebrovascular or peripheral vascular disease.